| scholarly article | Q13442814 |
| P2093 | author name string | Timothy B Niewold | |
| Consuelo M López de Padilla | |||
| P2860 | cites work | Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus | Q24530690 |
| Cross-regulation of TNF and IFN-alpha in autoimmune diseases | Q24556513 | ||
| Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study | Q24816844 | ||
| Structural Linkage between Ligand Discrimination and Receptor Activation by Type I Interferons | Q27671836 | ||
| The crystal structure of human interferon beta at 2.2-A resolution | Q27746372 | ||
| Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3 | Q27860854 | ||
| Pattern recognition receptors and inflammation | Q27861115 | ||
| Virus interference. I. The interferon | Q28181608 | ||
| Virus interference. II. Some properties of interferon | Q28181619 | ||
| A road map for those who don't know JAK-STAT | Q28201970 | ||
| Signal transduction by type I interferons | Q28210242 | ||
| Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus | Q28212039 | ||
| Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis | Q28213371 | ||
| Familial aggregation of autoimmune disease in juvenile dermatomyositis | Q28235854 | ||
| A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus | Q28236839 | ||
| Structure of the human type-I interferon gene cluster determined from a YAC clone contig | Q28243340 | ||
| Toll-like receptor signaling and IRF transcription factors | Q28244355 | ||
| IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes | Q28245089 | ||
| Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus | Q28246766 | ||
| Role of natural interferon-alpha producing cells (plasmacytoid dendritic cells) in autoimmunity | Q28246851 | ||
| Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis | Q28246912 | ||
| Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis | Q28251763 | ||
| IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus | Q28253129 | ||
| The receptor of the type I interferon family | Q28255299 | ||
| A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis | Q28257957 | ||
| IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors | Q28260114 | ||
| Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus | Q28261358 | ||
| Characterization of a soluble ternary complex formed between human interferon-beta-1a and its receptor chains | Q42080713 | ||
| Plasmacytoid dendritic cells regulate autoreactive B cell activation via soluble factors and in a cell-to-cell contact manner | Q42161963 | ||
| Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies. | Q43640120 | ||
| Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. | Q44088417 | ||
| Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study | Q45099936 | ||
| Interferon-α suppresses cAMP to disarm human regulatory T cells. | Q45955170 | ||
| Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab | Q46322942 | ||
| Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. | Q47368420 | ||
| Nomenclature of the human interferon genes | Q48787065 | ||
| Prolonged treatment with interferon alpha and peginterferon induces rheumatoid arthritis syndrome and erythema nodosum. | Q50568272 | ||
| The multifaceted balance of TNF-α and type I/II interferon responses in SLE and RA: how monocytes manage the impact of cytokines. | Q52888237 | ||
| A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. | Q53220648 | ||
| Expression of Toll-like receptor 3 and Toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines. | Q54435742 | ||
| Increased Sensitivity to Interferon-α in Psoriatic T Cells | Q56112095 | ||
| Activation of the endoplasmic reticulum stress response in autoimmune myositis: Potential role in muscle fiber damage and dysfunction | Q60591827 | ||
| Direct Stimulation of T Cells by Type I IFN Enhances the CD8+ T Cell Response during Cross-Priming | Q63952505 | ||
| Interferon-alpha 2 produced by normal human leukocytes is predominantly interferon-alpha 2b | Q72646630 | ||
| Serum interferon levels in patients with systemic lupus erythematosus | Q72664589 | ||
| Clustering of leukocyte and fibroblast interferon genes of human chromosome 9 | Q72677481 | ||
| Human type I interferons differ greatly in their effects on the proliferation of primary B cells | Q77766146 | ||
| Differential responses to IFN-alpha subtypes in human T cells and dendritic cells | Q79274218 | ||
| The Yin and Yang of TNF-{alpha} inhibition | Q79798751 | ||
| Association of IRF5 polymorphisms with systemic lupus erythematosus in a Japanese population: support for a crucial role of intron 1 polymorphisms | Q80800872 | ||
| Dysfunctional CD4+,CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells | Q80800895 | ||
| Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction | Q80955835 | ||
| A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies | Q80974116 | ||
| A bridge between interferon-alpha and tumor necrosis factor in lupus | Q81727256 | ||
| Immature muscle precursors are a source of interferon-β in myositis: role of Toll-like receptor 3 activation and contribution to HLA class I up-regulation | Q82561068 | ||
| Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway | Q84626226 | ||
| Biochemistry of Interferons and Their Actions | Q28262345 | ||
| Intermittent interferonemia and interferon responses in multiple sclerosis | Q28266361 | ||
| Brief Report: IRF5 systemic lupus erythematosus risk haplotype is associated with asymptomatic serologic autoimmunity and progression to clinical autoimmunity in mothers of children with neonatal lupus | Q28268287 | ||
| cDNA microarrays reveal distinct gene expression clusters in idiopathic inflammatory myopathies | Q28270002 | ||
| Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort | Q28271779 | ||
| Interferon alpha-induced lupus: proof of principle | Q28282720 | ||
| Gene-gene-sex interaction in cytokine gene polymorphisms revealed by serum interferon alpha phenotype in juvenile dermatomyositis | Q28287170 | ||
| Role of the STAT1-SH2 domain and STAT2 in the activation and nuclear translocation of STAT1 | Q28287881 | ||
| Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients | Q28290930 | ||
| TLR signaling | Q28291637 | ||
| Interferons, interferon-like cytokines, and their receptors | Q28293630 | ||
| Pathology of multiple sclerosis: where do we stand? | Q28296052 | ||
| Aberrant Type I Interferon Regulation in Autoimmunity: Opposite Directions in MS and SLE, Shaped by Evolution and Body Ecology | Q28299160 | ||
| An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity | Q28303311 | ||
| Interferons and their actions | Q28305734 | ||
| IRF-7 is the master regulator of type-I interferon-dependent immune responses | Q28511410 | ||
| Multiple sclerosis | Q29616022 | ||
| Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction | Q29620054 | ||
| Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis | Q33283212 | ||
| Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-alpha activity in lupus patients | Q33703923 | ||
| Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. | Q33731760 | ||
| Myofiber stress-response in myositis: parallel investigations on patients and experimental animal models of muscle regeneration and systemic inflammation | Q33923345 | ||
| Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? | Q33937489 | ||
| Conversion events in gene clusters | Q33974268 | ||
| Anti-double-stranded DNA antibodies, nucleosomes, and systemic lupus erythematosus: a time for new paradigms? | Q34175687 | ||
| Interferon-α induction and detection of anti-ro, anti-la, anti-sm, and anti-rnp autoantibodies by autoantigen microarray analysis in juvenile dermatomyositis | Q34214035 | ||
| Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) | Q34375520 | ||
| Baseline MxA mRNA expression predicts interferon beta response in multiple sclerosis patients. | Q34513928 | ||
| Gene conversion: mechanisms, evolution and human disease | Q34685613 | ||
| Interferon regulatory factors in human lupus pathogenesis | Q34988497 | ||
| Interferon regulatory factors: critical mediators of human lupus | Q35014051 | ||
| Rheumatoid arthritis following PEG-interferon-alfa-2a plus ribavirin treatment for chronic hepatitis C: a case report and review of the literature | Q35028863 | ||
| Genetic variants and disease-associated factors contribute to enhanced interferon regulatory factor 5 expression in blood cells of patients with systemic lupus erythematosus | Q35542816 | ||
| A gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells | Q35553508 | ||
| Expression of interferon beta in synovial tissue from patients with rheumatoid arthritis: comparison with patients with osteoarthritis and reactive arthritis | Q35555010 | ||
| Microarray analysis of interferon-regulated genes in SLE. | Q35675519 | ||
| Autoimmune disease risk variant of IFIH1 is associated with increased sensitivity to IFN-α and serologic autoimmunity in lupus patients | Q35832527 | ||
| Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells | Q35854122 | ||
| Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. | Q35953527 | ||
| Large-scale analysis of tumor necrosis factor α levels in systemic lupus erythematosus | Q36095071 | ||
| Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent | Q36234001 | ||
| Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance | Q36298955 | ||
| Evolution of the interferon alpha gene family in eutherian mammals | Q36326242 | ||
| Multiple sclerosis--the plaque and its pathogenesis | Q36410882 | ||
| Vasculitis associated with tumor necrosis factor-α inhibitors | Q36513081 | ||
| Ligand-induced association of the type I interferon receptor components | Q36553478 | ||
| TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity | Q36811126 | ||
| A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. | Q36851638 | ||
| Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients | Q37052138 | ||
| STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus | Q37070948 | ||
| Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupus | Q37073744 | ||
| Activation of the Interferon Pathway is Dependent Upon Autoantibodies in African-American SLE Patients, but Not in European-American SLE Patients | Q37208233 | ||
| Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. | Q37229729 | ||
| Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. | Q37277856 | ||
| Age- and sex-related patterns of serum interferon-alpha activity in lupus families | Q37312612 | ||
| Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept | Q37331753 | ||
| Anti-TNF-induced lupus | Q37471071 | ||
| Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists | Q37524952 | ||
| Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: a systematic literature review based on 222 cases | Q38041861 | ||
| Pre-assembly of STAT4 with the human IFN-alpha/beta receptor-2 subunit is mediated by the STAT4 N-domain | Q40210236 | ||
| Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation | Q40298486 | ||
| Transient transfection of mouse fibroblasts with type I interferon transgenes provides various degrees of protection against herpes simplex virus infection | Q40701442 | ||
| Analysis of the antiviral activities of natural IFN-alpha preparations and their subtype compositions | Q40768286 | ||
| Exacerbations of multiple sclerosis in patients treated with gamma interferon | Q40797798 | ||
| Different relative activities of human cell-derived interferon-alpha subtypes: IFN-alpha 8 has very high antiviral potency | Q41147973 | ||
| Elucidation of the basic three-dimensional structure of type I interferons and its functional and evolutionary implications. | Q41511507 | ||
| Structure-activity of type I interferons | Q41567642 | ||
| The evolution of the type I interferon gene family in mammals | Q41654075 | ||
| Rheumatoid arthritis induced by alpha-interferon therapy | Q41918975 | ||
| Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjögren's syndrome autoantigen-associated RNA. | Q41945272 | ||
| P433 | issue | 1 Pt 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | inflammation | Q101991 |
| P304 | page(s) | 14-21 | |
| P179 | part of the series | Gene Wiki Review Series | Q108807010 |
| P577 | publication date | 2015-09-24 | |
| P1433 | published in | Gene | Q5531065 |
| P1476 | title | The type I interferons: Basic concepts and clinical relevance in immune-mediated inflammatory diseases | |
| P478 | volume | 576 |
| Q57297471 | ARID3a gene profiles are strongly associated with human interferon alpha production |
| Q37224632 | Alterations in nuclear structure promote lupus autoimmunity in a mouse model. |
| Q39283180 | Bone Marrow-Derived Mesenchymal Stem Cells From Patients With Systemic Lupus Erythematosus Have a Senescence-Associated Secretory Phenotype Mediated by a Mitochondrial Antiviral Signaling Protein-Interferon-β Feedback Loop. |
| Q40510052 | Gene therapy with plasmids encoding IFN-β or IFN-α14 confers long-term resistance to HIV-1 in humanized mice |
| Q38726782 | Genetics of autoimmune diseases: perspectives from genome-wide association studies |
| Q52897553 | Genetics of human lupus nephritis. |
| Q28071495 | Hematopoietic Stem Cell Regulation by Type I and II Interferons in the Pathogenesis of Acquired Aplastic Anemia |
| Q59805361 | IFN-β Plays Both Pro- and Anti-inflammatory Roles in the Rat Cardiac Fibroblast Through Differential STAT Protein Activation |
| Q27469008 | Identification of Novel Inhibitors of the Type I Interferon Induction Pathway Using Cell-Based High-Throughput Screening |
| Q52646149 | Interleukin-1β Signaling in Dendritic Cells Induces Antiviral Interferon Responses. |
| Q99240942 | JAK/STAT pathway in pathology of rheumatoid arthritis (Review) |
| Q33731336 | Meta-analysis of host response networks identifies a common core in tuberculosis. |
| Q97559063 | NCoR1 fine-tunes type-I IFN response in cDC1 dendritic cells by directly regulating Myd88-IRF7 axis under TLR9 |
| Q112715271 | Phosphor-IWS1-dependent U2AF2 splicing regulates trafficking of CAR-E-positive intronless gene mRNAs and sensitivity to viral infection |
| Q37281571 | Prolonged activation of innate antiviral gene signature after childbirth is determined by IFNL3 genotype |
| Q47129970 | Single-cell gene expression patterns in lupus monocytes independently indicate disease activity, interferon and therapy |
| Q26746697 | Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway |
| Q45909750 | The MEK Inhibitors Trametinib and Cobimetinib Induce a Type I Interferon Response in Human Keratinocytes. |
| Q47990642 | Therapeutic Modulation of Plasmacytoid Dendritic Cells in Experimental Arthritis. |
| Q58760914 | Topical Plant Polyphenols Prevent Type I Interferon Signaling in the Skin and Suppress Contact Hypersensitivity |
| Q93236923 | Type I interferon |
Search more.